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Introduction
Pulmonary diseases remain among the top 5 causes of  death worldwide according to the World Health 
Organization (1, 2). Lung cancer is the leading cause of  cancer-related deaths globally, and despite recent 
treatment advances, the 5-year survival rate has not improved substantially in the past 20 years (3). Chronic 
obstructive pulmonary disease (COPD) (4) and idiopathic pulmonary fibrosis (IPF) (5) are devastating lung 
Complexity of lung microenvironment and changes in cellular composition during disease make 
it exceptionally hard to understand molecular mechanisms driving development of chronic lung 
diseases. Although recent advances in cell type–resolved approaches hold great promise for 
studying complex diseases, their implementation relies on local access to fresh tissue, as traditional 
tissue storage methods do not allow viable cell isolation. To overcome these hurdles, we developed 
a versatile workflow that allows storage of lung tissue with high viability, permits thorough sample 
quality check before cell isolation, and befits sequencing-based profiling. We demonstrate that 
cryopreservation enables isolation of multiple cell types from both healthy and diseased lungs. 
Basal cells from cryopreserved airways retain their differentiation ability, indicating that cellular 
identity is not altered by cryopreservation. Importantly, using RNA sequencing and EPIC Array, we 
show that gene expression and DNA methylation signatures are preserved upon cryopreservation, 
emphasizing the suitability of our workflow for omics profiling of lung cells. Moreover, we 
obtained high-quality single-cell RNA-sequencing data of cells from cryopreserved human lungs, 
demonstrating that cryopreservation empowers single-cell approaches. Overall, thanks to its 
simplicity, our workflow is well suited for prospective tissue collection by academic collaborators 
and biobanks, opening worldwide access to viable human tissue.
2
T E C H N I C A L  A D V A N C E
JCI Insight 2021;6(6):e140443  https://doi.org/10.1172/jci.insight.140443
diseases characterized by progressive airflow limitation and tissue scarring, respectively. To date, limited 
therapeutic options are available for COPD and IPF; thus, major efforts are made in both academic labs 
and pharmaceutical industries (4, 6–8) to identify novel drugs targeting key molecular pathways involved in 
the pathogenesis of  these diseases.
Recent advances in next-generation sequencing (NGS) platforms have revolutionized biomedical sci-
ences and the approach to study complex physiological and pathological processes, moving from classical 
1-gene studies to a more comprehensive analysis of  gene networks (9, 10). NGS-based genetic and epigene-
tic studies provided the first unbiased maps of  lung diseases, leading to the identification of  key dysregulat-
ed pathways and the discovery of  potential disease drivers (11–17). Moreover, the robustness of  epigenetic 
profiling allowed proper classification of  cancers of  unknown primary origin (18), altogether opening the 
door for better and personalized treatments. Thus, given the specificity of  gene expression and epigenetic 
profiles, NGS-based profiling strategies hold great promise for biomarker discovery and personalized med-
icine applications, allowing more precise diagnosis, patient stratification, and even follow-up of  patient 
response to treatment (9, 19–21).
Despite these technological advances, a deep understanding of  molecular mechanisms underlying the 
development of  complex lung pathologies is hindered by the heterogeneity of  the lung microenvironment 
(22) and by changes in cellular number and composition during disease progression (15, 17, 23–26), which 
cannot be resolved with bulk tissue studies. Hence, NGS-based approaches providing cellular resolution, 
like profiling of  defined cell populations or single-cell analyses, need to be implemented to identify cell 
types driving distinct disease phenotypes. Critically, successful implementation of  such experiments is diffi-
cult due to shortcomings of  human tissue access, tissue quality, and storage platforms.
Foremost, typical lung tissue storage formats offered by biobanks, like flash-frozen or formalin-fixed 
paraffin-embedded (FFPE) tissue, do not allow viable cell isolation and are therefore not easily compatible 
with single-cell transcriptome analysis or with epigenetic profiling of  defined cell populations. Alterna-
tive strategies involving access to fresh tissue via collaborations with local hospitals restrict tissue access 
geographically. In addition, working with fresh tissue does not allow its thorough histological evaluation 
before sample processing. Importantly, the quality of  clinical samples is crucial for the discovery of  dis-
ease-relevant changes using NGS-based technologies. For example, the presence of  tumor cells, fibrosis, 
or inflammation in samples selected as controls can significantly increase the experimental noise, masking 
differential gene expression and epigenetic changes caused by the disease of  interest. To circumvent this 
problem, typically, a very large number of  samples must be analyzed, or samples are discarded a posteriori 
when tissue quality is poor. Both strategies, however, are incompatible with expensive and time-consuming 
NGS-based experiments, like single-cell RNA-Seq or whole-genome DNA methylation analyses.
Driven by these difficulties existing in the field, we revisited the literature to identify protocols compati-
ble with long-term storage of  viable tissue samples (27–31) and established a simplified lung tissue process-
ing workflow that enables tissue collection and expands geographical barriers. We introduced an essential 
tissue quality check step, where an experienced lung pathologist reviewed the samples before cell isolation 
and NGS-based profiling. We demonstrate that cryopreservation does not compromise tissue viability and 
is suitable for isolating multiple cell types from different lung locations. It is applicable to both healthy and 
diseased lung tissue, including tumors, and it is compatible with NGS-based transcriptional and epigenetic 
profiling of  cells of  interest, including single-cell approaches. We also show that cells isolated from cryopre-
served human tissue can be used for in vitro validation in cellular models.
Results
Lung tissue processing workflow. Due to the substantial cost of  the NGS-based whole-genome analyses, such 
as whole-genome bisulfite sequencing or single-cell RNA-Seq, only a limited number of  samples are typ-
ically analyzed to derive disease signatures. Such setup should be combined with a strict tissue quality 
analysis to ensure the best possible separation between control and disease groups and the inclusion of  
high-quality material only. Consequently, we include a cryopreservation step in our experimental workflow 
to allow a thorough quality check of  the tissue samples before performing further downstream assays. Our 
complete workflow consists of  4 steps: (a) tissue collection and preservation, (b) tissue quality check, (c) cell 
isolation, and (d) NGS-based profiling (Figure 1). Each step is detailed below.
Tissue collection and preservation. First, patient inclusion criteria should be defined for prospective tissue 
collection studies to ensure the best possible matching of  control and disease groups in terms of  age, sex, 
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smoking status, and smoking history. In addition, whenever possible, the medical history of  the patients 
should be gathered, for the best possible characterization of  the included specimens. This study aimed to 
evaluate the feasibility and promise of  human lung tissue cryopreservation for transcriptomic and epi-
genetic profiling with cell type resolution. Thus, lung tissue samples (parenchyma from healthy controls, 
COPD patients, and lung tumors) were collected in transport medium (Supplemental Table 1 and Sup-
plemental Table 11; supplemental material available online with this article; https://doi.org/10.1172/jci.
insight.140443DS1) and sent to one of  the laboratories involved in the study. At arrival, several representa-
tive pieces from different parts of  the tissue were collected and fixed in formalin for subsequent histological 
analysis (Figure 1A and Supplemental Table 2). The remaining material was separated into 3 distinct com-
partments via manual microscopic dissection, as follows: (1) airway and vessel enriched; (2) airway-free, 
tumor-free parenchyma; and (3) tumor fraction (Figure 1A). This step was introduced as it allows an easy 
initial pre-enrichment of  different lung compartments, for example, airway versus parenchyma, for subse-
quent cell isolation. After compartmentalization, the tissue was cut into small sections and cryopreserved 
for long-term storage (see Methods section for details).
Cryopreservation enables careful tissue quality control. Representative tissue slides stained with hematoxylin 
and eosin (H&E) were carefully evaluated by an experienced lung pathologist for the presence of  emphyse-
ma, immune infiltrates, fibrosis, as well as other alterations (Figure 1B). This histopathological assessment, 
together with lung function test results available from clinical records, allows better classification of  the 
collected material. Critically, this step enables the exclusion of  low-quality samples, which is essential for 
the discovery of  disease-relevant changes. Remarkably, out of  6 tested “control” samples from donors with 
preserved lung function and normal radiographic analysis (Figure 2A), only 2 (33%) showed normal his-
tological patterns (Figure 2, B and C). The other 4 tissue samples showed moderate fibrosis with different 
grades of  chronic inflammation (Figure 2, D–G). Notably, all 6 “control” patients had shown normal spi-
rometry values as measured by FEV1/FVC and FEV1 value close to 100%, demonstrating the importance 
of  the histological quality check (Figure 2A). Similarly, when evaluating diseased samples from patients 
with COPD (Figure 2, H–J), 1 showed moderate fibrosis with thickening of  the alveolar walls and chronic 
inflammation (Figure 2J). For the tumor tissues (Figure 2, K–M), 1 of  the samples contained a consid-
erable amount of  normal adjacent tissue (Figure 2M). For samples with high healthy epithelial content, 
preisolation of  tumor cells might be essential to identify tumor-specific signatures and prevent overgrowth 
of  the healthy tissue for functional organoid assays (32–34). In summary, these observations demonstrate 
that careful histological evaluation of  the samples is a critical step before undergoing lengthy cell isolation 
procedures and expensive downstream sequencing. Selecting proper control and diseased samples based 
not only on available patient medical data but also on tissue quality will result in more meaningful and 
unambiguous results during data analysis.
Cryopreservation does not compromise cell viability. To analyze the viability of the cryopreserved lung tissue, 
tumor-free lung parenchyma as well as tumor samples obtained from 4 donors were processed as follows. First, 
samples were halved, and one part was cryopreserved. The other half  of the tissue was dissociated to generate 
a single-cell suspension. Cell viability of the total suspension, as well as of the epithelial and immune fractions 
specifically, was evaluated by flow cytometry using SyTOX staining. Similarly, after 1- or 2-week storage, cryo-
preserved samples were thawed, dissociated, and processed for comparison with the fresh tissue obtained from 
the same donor. Although we observed a mild (5% to 10%) viability drop after cryopreservation (Figure 3A and 
Supplemental Figure 1, A–G), with median viability of 90% for fresh parenchyma (viability range 86%–94%) 
and of 84% for cryopreserved samples (78%–94%), the differences were nonsignificant (n = 4, P = 0.125, 
nonparametric paired Wilcoxon’s test), and both fresh and frozen samples showed high viability with values 
above 80%. Similar results were obtained for the tumor samples (Figure 3A, with 88%–95% viability for fresh 
tumor and 85%–90% for cryopreserved tumor), where no significant differences (n = 4, P = 0.125) in viability 
were obtained in the total tissue or specific epithelial or immune cell compartments (Supplemental Figure 1, B, 
C, and E). Moreover, we successfully cryopreserved tissue from smokers with preserved lung function (n = 6, 
viability average = 83.2%), as well as smokers with various stages of COPD (n = 13, viability average = 82.7%) 
(Figure 3A), maintaining viability above 80%, indicating that this protocol can be used to profile both normal 
and COPD tissue. We, therefore, conclude that the cryopreservation protocol used here preserves tissue viabil-
ity, and thus, is suitable for isolating viable cells from cryopreserved material.
Multiple cell types can be isolated from cryopreserved lung tissue. To assess the compatibility of  cryopreserva-
tion with the isolation of  defined cell populations, which could further be subjected to NGS-based profiling 
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or used for validation studies in vitro, we isolated different mesenchymal and epithelial cell populations 
from cryopreserved lung tissues as described below.
First, human lung fibroblasts were successfully derived by explant outgrowth from both parenchyma 
and airway-enriched lung compartments, yielding parenchymal and peribronchial human lung fibroblast 
populations, respectively (Figure 3B). Immunostaining with antibodies against mesenchymal markers 
(vimentin and α–smooth muscle actin), complemented with FACS analysis of  epithelial (EPCAM) and 
immune (CD45) markers (Figure 3B and Supplemental Figure 1H), demonstrated high fibroblast purity, 
indicating that tissue compartmentalization and cryopreservation are compatible with fibroblast isolation 
from different lung locations. Importantly, as peribronchial and parenchymal fibroblasts show distinct 
phenotypes (35–37), protocols enabling lung compartmentalization before cell isolation are crucial for 
understanding specific roles of  different fibroblast populations in the development of  respiratory diseases.
Second, epithelial cells from cryopreserved airways, parenchymal tissue, and tumor fractions were puri-
fied using different protocols (Figure 3C). Human basal epithelial cells and distal alveolar epithelial cells 
were successfully isolated by explant outgrowth from cryopreserved large and small airways or parenchy-
ma, respectively (Figure 3C and Supplemental Figure 1I, sprout). In addition, parenchyma-derived alveolar 
Figure 1. Overview of the tissue processing workflow presented in this study. (A) Lung dissection and preparation for histology and cryopreservation of 
lung tissue and tumor samples. (B) Tissue quality control steps, including embedding, H&E staining, and pathological evaluation of the tissue. (C) Live cell 
isolation for profiling and in vitro culture. (D) Next-generation sequencing–based profiling, including RNA-Seq, DNA methylation EPIC Array (850K array), 
and single-cell RNA-Seq (scRNA-Seq). (E) Generation of 2D and 3D patient-derived cellular models from cryopreserved tissue. Legend is displayed on the 
bottom right. EPCAM, epithelial cell-adhesion molecule.
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epithelial cells were obtained upon thawing, tissue dissociation, and cell seeding on culture dishes or by 
FACS gating for EPCAM+/CD45 cells (Supplemental Figure 1I). Tumor cells were isolated from cryopre-
served lung squamous cell carcinomas (SCCs) upon dissociation and seeding (Figure 3C). The purity of  the 
epithelial cells was shown by immunofluorescence and FACS (Figure 3C; Supplemental Figure 1, H and I; 
and Supplemental Figure 3B), using cell type–specific markers.
Overall, these results show that the cryopreservation protocol described here permits successful isola-
tion and culture of  cells from defined lung compartments (airways, parenchyma, and tumors), encompass-
ing different lineages (mesenchymal and epithelial) using alternative isolation methods (FACS, explant 
outgrowth, or differential seeding after tissue dissociation).
Cellular identity and functions are not altered because of  cryopreservation. Basal cells are the epithelial 
progenitors of  the human airways (38, 39), which, under specific conditions, can differentiate into cil-
iated and secretory cells. To evaluate the impact of  cryopreservation on the progenitor capabilities of  
basal epithelial cells, we used a well-established 3D model to generate bronchospheres (40–42). When 
cultured in ultra-low attachment plates with 5% Matrigel, basal cells derived from cryopreserved air-
ways recapitulated the pseudostratified epithelium observed in vivo as shown by the expression of  
Figure 2. Importance of thorough tissue quality control before cell isolation and profiling. (A) Table showing spirometry values (forced expiratory volume 
in 1 s/forced vital capacity ratio [FEV1/FVC] and FEV1) of 6 normal donors. (B–G) Representative H&E images of lung parenchyma from each of the donors 
listed in the table (A). (B and C) Examples of donors with healthy lungs. (D–G) H&E images showing slight to moderate fibrosis with mild (G) and moderate 
(D–F) chronic inflammation and desquamative reaction (E). Donor D also presents anthracotic pigment deposits along the bronchovascular bundles. (H) 
Table summarizing the characteristics of 2 exemplary COPD donors. (I and J) corresponding H&E images showing mild to moderate emphysema (donor 
I) and moderate fibrosis with thickening of the alveolar walls and chronic inflammation (donor J). (K) Table indicating tumor type and presence/absence 
of healthy epithelium. (L and M) Exemplary images of 2 lung squamous cell carcinoma (SCC) samples. Tumor L represents a sample with very high tumor 
purity, whereas tumor M shows the invasion front of a non–small cell lung cancer specimen with intra-alveolar tumor spread (STAS; left side) and a signifi-
cant amount of healthy lung parenchyma with mild emphysema on the right. Scale bars: 0.2 mm. –, absent; +, present.
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Figure 3. Cell viability and function are maintained in cryopreserved lung samples. (A) FACS quantification of viable cells from dissociated lung 
tissues using SyTOX blue as a viability dye. Comparison between fresh and cryopreserved lung parenchyma (left) and lung tumor (middle) from 4 
donors showing overall viability values above 80% (NS, nonsignificant, P value= 0.125, n = 4, Wilcoxon’s matched pairs signed-rank test). Right, 
the viability of single-cell suspensions obtained from cryopreserved tissue of healthy control donors (n = 6) and COPD (n = 13) samples (NS, P value 
= 0.865, Mann-Whitney test). (B) Immunofluorescence images of fibroblasts derived from cryopreserved lung parenchyma (left) and small airway 
(right), demonstrating expression of a mesenchymal marker (vimentin, green). Discrete fibroblasts expressing α–smooth muscle actin (red) are also 
present. (C) Immunofluorescence images of different epithelial cells isolated from cryopreserved material including basal cells from large (top left 
panel) and small airways (top right panel), distal epithelial cells from parenchyma (bottom left), and tumor epithelial cells derived from lung SCC 
showing expression of the epithelial marker EPCAM (red). (D) Basal cell–derived spheres show that basal cells (TP63+, red; KRT5+ green, as indicated 
on the panels) derived from cryopreserved airways are functional and can differentiate into goblet (MUC5AC+, green) and ciliated cells (FOXJ1+, red). 
(B–D) All the nuclei were counterstained with DAPI (blue); scale bars: 50 μm.
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basal (tumor protein p63 [TP63], keratin 5 [KRT5]), goblet (mucin 5AC [MUC5AC]), and ciliated 
(forkhead box J1 [FOXJ1]) cell markers (Figure 3D).
These results indicate that lung tissue cryopreservation does not interfere with the isolation of  basal 
cells or with their progenitor capacity. Notably, as the 3D sphere system allows high-throughput studies to 
model growth, repair, and airway cell differentiation (40), our protocol could facilitate the development of  
well-characterized patient-derived cellular assays for in vitro studies.
Cryopreservation preserves transcriptional and epigenetic signatures of  cells. To directly evaluate the impact of  
tissue cryopreservation on the molecular signatures of  isolated cells, we obtained genome-wide transcrip-
tional and epigenetic profiles of  primary human lung fibroblasts derived by explant outgrowth from fresh 
and cryopreserved lung parenchyma. For this, lung tissue pieces of  3 independent donors were halved; one 
part was used to isolate fibroblasts from fresh parenchyma, and the other half  underwent cryopreservation 
before cell isolation (Figure 4A). Importantly, 2 to 5 areas from each patient were included as technical 
replicates to cover the heterogeneity of  the human lung parenchyma.
We consistently obtained good yield and quality of  the isolated RNA, as indicated by the RNA integrity 
number (RIN) higher than 8.0 for all samples. To minimize potential technical batch artifacts in the RNA-
Seq experiment, RNA isolation, library preparation, and sequencing of  all samples were performed simulta-
neously. All samples exhibited equally high alignment rates and could be efficiently assigned to the reference 
gene annotation (alignment statistics are shown in Supplemental Table 9; read count table is provided as 
Supplemental Table 12), indicative of  high-quality RNA-Seq data. Notably, principal component analysis 
(PCA) of  the 500 most variable genes revealed that transcriptome differences between donors represented 
the highest variance in the data (Figure 4B), and thus, samples derived from the same donor grouped when 
using unsupervised hierarchical clustering (Supplemental Figure 2C). Critically, a thorough inspection of  the 
first 10 principal components, representing 90% of  the total variance in the data, did not reveal a separation 
of  cryopreserved and fresh samples (Supplemental Figure 2, A and B). In summary, the RNA-Seq results 
indicate that transcriptional signatures of  the fresh and cryopreserved samples are highly similar, and no 
strong gene expression signatures associated with the tissue cryopreservation treatment can be identified.
In parallel, to investigate possible effects of  cryopreservation on epigenetic modifications, we performed 
genome-wide DNA methylation profiling using Human Infinium MethylationEPIC Array on an analo-
gous set of  fibroblast samples isolated from fresh and cryopreserved material of  the same donors. Quality 
check, filtering, and normalization of  methylation data were performed with the RnBeads pipeline (43) as 
described in Methods. All samples had a good separation of  foreground and background signal according to 
the internal control probes. Global Euclidean distance-based clustering analysis of  data did not reveal a clear 
cluster structure, with fresh and cryopreserved samples of  different donors evenly interspersed (Supplemen-
tal Figure 2F). The PCA using the data of  all high-quality CpG positions revealed that the major variability 
was related to donor-specific DNA methylation effects. As for the RNA-Seq data, there was no separation 
between cryopreserved and fresh samples in any of  the planes spanned by pairs of  principal components 
(Figure 4C and Supplemental Figure 2, D and E). The individual-specific variation was stronger than other 
effects, including cryopreservation, as can be seen in the clustering heatmap of  the 5000 most variable CpG 
positions (Supplemental Figure 2F). Finally, differential methylation analysis for association with the cryo-
preservation indicator variable did not detect any significantly altered CpG sites after adjustment for multi-
ple testing (under FDR of  0.05), allowing us to conclude that there are no major effects of  cryopreservation 
on the genome-wide scale in DNA methylation profiles. Altogether, these results emphasize the suitability of  
cryopreservation for the cell type–resolved transcriptional and epigenetic profiling of  lung cells.
Tissue cryopreservation enables high-quality single-cell transcriptomic analysis of  isolated lung cells. Recent 
advances in single-cell omics profiling have revolutionized biomedical research, allowing identification of  
novel cell types (44–46), reconstruction of  developmental trajectories (47), and fine-mapping of  disease 
states (15–17, 23–26, 48), holding great promise for biomarker discovery and personalized medicine appli-
cations. However, as they rely on very high cell viability and integrity, single-cell profiling studies typically 
require access to fresh tissue, restricting complex experimental designs.
Encouraged by the high viability of  our cryopreserved lung tissue, we evaluated the possibility of  using 
our workflow for single-cell transcriptomics. For this aim, we dissociated cryopreserved lung parenchyma 
of  3 control donors with normal lung function and morphologically healthy lung (based on pathologist 
evaluation); 2 of  them (HLD11 and HLD15) were stored in liquid nitrogen for 2 years. To reduce complex-
ity, we enriched for epithelial cell populations (EPCAM+) using FACS and performed single-cell RNA-Seq 
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with the Chromium 10x Genomics technology (Figure 4D and Supplemental Figure 3, A and B). Evalua-
tion of  standard single-cell RNA-Seq quality control parameters demonstrated the high quality of  the gen-
erated single-cell data (Figure 4E and Supplemental Table 10). Importantly, a comparison between our data 
(cryo-BX, n = 3) and 47 publicly available human data sets (fresh, n = 11; frozen, n = 36) that used the same 
10x Genomics 3′ mRNA v2 chemistry revealed that the quality of  our data significantly outperformed 
Figure 4. Transcriptional and epigenetic profiles of cells are maintained in cryopreserved lung tissue. (A) Overview of the approaches used for compar-
ing genome-wide transcriptional and epigenetic profiles of primary human lung fibroblasts derived from fresh and cryopreserved lung tissue explants of 3 
donors. (B) Principal component analysis (PCA) of the 500 most variable expressed genes obtained from RNA-Seq across all samples. (C) PCA of the 5000 
most variable CpG positions revealed by methylation profiling. (D) Schematic overview of tissue processing for scRNA-Seq of sorted epithelial cells obtained 
from cryopreserved parenchyma of 3 control donors. (E) Representative quality reports comparing scRNA-Seq data obtained in this study (cryo-BX, green 
box plot, n = 3) with 47 publicly available human data sets from fresh (orange box plot, n = 11) and frozen tissue (blue box plot, n = 36). The box plots depict 
the minimum and maximum values (whiskers), the upper and lower quartiles, and the median. The length of the box represents the interquartile range. (F) 
Uniform Manifold Approximation and Projection (UMAP) clustering indicating the main epithelial cell types identified in the epithelial cell–enriched sorted 
lung parenchyma, including alveolar type I (ATI) and type II (ATII), ciliated, goblet, club, basal, as well as alveolar progenitor cells. Besides the indicated epi-
thelial cells, fibroblasts, smooth muscle cells, pulmonary neuroendocrine cells (PNECs), as well as vascular endothelial and lymphatic endothelial cells, were 
also identified. Fibroblasts and smooth muscle cells were brought closer for aesthetic reasons. (G) Total number of identified cells as well as the averaged 
percentage and the total number of the different cell populations identified by scRNA-Seq in each of the profiled patients, indicating high reproducibility of 
the protocol. Vas, vascular endothelial cells; Lym, lymphatic endothelial cells.
9
T E C H N I C A L  A D V A N C E
JCI Insight 2021;6(6):e140443  https://doi.org/10.1172/jci.insight.140443
data obtained from frozen samples and was similar to data obtained from fresh samples (Figure 4E and 
Supplemental Table 10). Unbiased clustering performed on all cryo-BX samples and 19,100 cells led to the 
robust identification of  12 distinct cell populations (Figure 4F and Supplemental Tables 13 and 14). Cell 
clusters were annotated based on commonly used markers in the literature, as well as genes that were differ-
entially expressed among cell clusters (Supplemental Figure 3C and Supplemental Table 15). We identified 
all major epithelial cell populations in the distal lung: ATII, ATI, basal, ciliated, and secretory cells. In 
addition, we identified rare cell populations such as PNECs and putative progenitor cells that express ATI, 
ATII, as well as proliferation markers. Apart from epithelial cells, which constituted 97.4% (n = 18,602) 
of  all cells, we also captured 2 endothelial (1.9%, n = 370) and 2 stromal (0.7%, n = 128) cell populations. 
Importantly, all cell populations were detected in all 3 donors (Figure 4G), highlighting the reproducibility 
of  the workflow. These data indicate that our cryopreservation workflow preserved high cell viability and 
integrity and is, therefore, suitable for droplet-based single-cell transcriptome profiling.
Discussion
The complexity of  the lung microenvironment together with changes in cellular composition occurring during 
disease progression limits our understanding of  molecular mechanisms leading to the development of  chronic 
lung diseases and the identification of  cell types and changes driving disease phenotypes. Although recent 
advances in cell type–resolved NGS approaches and single-cell profiling hold great potential for deconvolu-
tion of  complex disease traits, their implementation greatly relies on local access to fresh tissue. Similarly, the 
establishment of  disease-relevant models based on well-characterized patient-derived primary cells requires a 
regular supply of  fresh lung tissue. Therefore, local tissue access is one of  the main limitations for the imple-
mentation of  research projects based on human samples that have high translational potential.
To overcome this hurdle, we developed and validated a versatile workflow that allows long-term storage 
of  lung tissue samples without compromising cell viability. Our protocol permits thorough histological char-
acterization of  lung specimens before cell isolation and enables cell type–resolved transcriptional and epi-
genetic sequencing-based profiling of  human lung samples (Table 1). Importantly, our protocol, compared 
with more complex methods published previously, like cryopreservation of  hPCLS (28), PDX-CP (27), or 
cryopreservation of  digested lung cell suspensions (49), is much simpler. The overall tissue processing does 
not require any specialized equipment, can be carried out in any laboratory equipped with a cell culture 
room, and typically requires less than 1 hour for 4 g of  lung tissue. Therefore, due to its simplicity, this 
versatile protocol can be easily implemented in biobanks and research laboratories, as demonstrated by our 
successful collaboration with the Asklepios Biobank (Germany) and the research group of  Karmouty-Quin-
tana (USA) in the present study. Consequently, our workflow opens worldwide access to viable tissue and 
facilitates future international collaborations and the recruitment of  experts at different site locations. Addi-
tionally, disconnecting time and location of  the tissue collection from the downstream analysis provides 
further advantages, such as easier logistics, flexibility with experimental planning, and possibility of  complex 
experimental designs requiring specific equipment, such as FACS or single-cell separation devices.
Critically, our workflow includes a step of  detailed characterization of  the tissue samples before down-
stream analysis and is, therefore, particularly recommended for studies employing cell type–resolved NGS-
based platforms (like single-cell transcriptomic profiling or whole-genome bisulfite sequencing) that are both 
time-consuming and expensive, and allow processing of  only limited sample numbers. Although the imple-
mentation of  the strict tissue quality step results in a significant dropout of  lung samples before cell isola-
tion, it results in a controlled setup, where control and disease groups are divided not only based on clinical 
parameters (like spirometry or chest tomography) but also based on histopathology of  the same tissue piece 
that is used for downstream analysis. As shown in this study, this step is particularly important for sam-
ples from control (nondiseased) donors, which, despite preserved lung function parameters, often display 
histopathological changes (e.g., emphysema or severe immune infiltration). This is also the case for tumor 
samples, where high epithelial content of  healthy surrounding tissue would lead to confounding results in 
downstream analysis. Better sample classification reduces experimental noise, provides clearer disease traits, 
and consequently allows analyzing smaller sample sizes, significantly lowering sequencing costs.
Using primary human lung fibroblasts as a model, we demonstrate the suitability of our protocol for 
genome-wide transcriptional and epigenetic profiling of defined cell populations derived from cryopreserved 
lung tissue. Our results indicate that donor-specific transcriptional and epigenetic patterns are preserved during 
the cryopreservation of lung samples. Earlier this year, a protocol for biobanking of cryopreserved lung cell 
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suspensions for transcriptomic analysis was developed (49). Our mRNA sequencing of parenchymal lung 
fibroblasts confirms the results of Chu et al. obtained from FACS-sorted ATII and ATI cells using exome 
capture technology (49) and further emphasizes the suitability of cryopreservation for bulk RNA-Seq of iso-
lated cell populations. Moreover, we demonstrate that DNA methylation patterns of lung fibroblasts are main-
tained during cryopreservation, suggesting that our protocol is suitable for the epigenetic analysis of isolated 
lung cells. To our knowledge, this has not been demonstrated systematically before for lung tissue. Hence, 
cryopreservation of lung tissue pieces could be an alternative approach to cell suspension cryopreservation 
for lung tissue biobanking. Notably, cryopreservation enables processing of samples from multiple donors in 
parallel, minimizing technical biases related to multiple batch processing of fresh samples often observed in 
NGS-based analysis (50). Similarly, our workflow allows generation of excellent-quality single-cell RNA-Seq 
data from whole cells based on cryopreserved material and reliable identification of multiple epithelial lung 
cell types, including fragile cells, like ATI or secretory cells, demonstrating that they can be efficiently isolated 
from the cryopreserved lung tissue. With the development of single-cell transcriptomic technologies and large 
collaborative single-cell initiatives, like the Human Cell Atlas Project (51–53), various human tissue-processing 
approaches have been developed. The majority of single-cell studies of the human lung to date relied on direct 
processing of the collected fresh lung tissue (15–17, 25, 46, 48, 54). However, direct tissue processing at the 
clinic is usually not practical, may introduce batch effects, and prevents selection of good-quality tissue based 
on histological analysis. Alternatively, collected samples can be preserved and stored either as tissue or in a 
dissociated form as single-cell suspensions. Madissoon et al. benchmarked the short-term cold preservation of  
3 human tissues (spleen, esophagus mucosa, and lung) for single-cell RNA-Seq analysis and found little effect 
of cold ischemic time on the quality of the obtained data within the first 24 hours (55). Additional studies 
assessed a range of cell fixation methods. Several fixatives, including PFA (56), reversible cross-linker dithio-
bis(succinimidyl propionate) (57), methanol (58–60), and other stabilizing agents (61) have previously allowed 
the generation of single-cell RNA-Seq data from dissociated cells and tissues. However, fixation created a 
detectable 3′ bias compared with fresh cells (57). Using established cell lines and primary human cells, several 
Table 1. Preservation protocol for lung tissue
BX-LP (this study) Chu-LS (49) hPCLS (28) PDX-CP (27) Roth (31) RNA later Flash frozen FFPE blocks
Biobanking † †A † †A † † † †
Histology 
analysis
† na † † na †
RNA-Seq † † na na na †B †B ‡B




† na na na na †B ‡B
Proteomics na na na † na




















Healthy Lung cancer, 
COPD, IPF
Not specified Any Any Any
Applications of BioMed X lung protocol (BX-LP) for molecular profiling and primary cell culture compared with previously published lung preservation 
protocols (27, 28, 31, 49) and typical biobank tissue storage formats (table adapted from ref. 27). Biobanking considers the simplicity of the protocol, 
workload, as well as requirement for specialized equipment. Histology analysis considers the feasibility of performing histopathological quality analysis 
of the tissue slices (e.g., based on H&E staining). RNA-Seq, scRNA-Seq, DNA methylation, and proteomics profiling consider the feasibility of using the 
material for molecular profiling and indicate whether the cell type–specific resolution is possible. Cell culture considers feasibility of viable cell isolation 
and long-term culture. †Appropriate protocol for method. ‡Protocol with limited utility for method. —Protocol not suitable for method. AWork intensive or 
requires specialized equipment. BAppropriate for bulk tissue analysis but not for cell type–resolved analysis unless cell microdissection is used. CSuitable 
for single-nucleus RNA-Seq but not scRNA-Seq. Chu-LS, lung suspension cryopreservation; hPCLS, human precision-cut lung slice cryopreservation; PDX-
CP, pseudo-diaphragmatic expansion-cryoprotectant perfusion; na, not analyzed.
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studies demonstrated that DMSO-based cell cryopreservation does not alter global transcriptional profiles of  
cells (29, 59, 62), despite reduced viability (29). Few studies also demonstrated the suitability of cryopreserva-
tion of human tissues — ovarian carcinoma (29), renal biopsies (30), and synovial tissue (63) — for subsequent 
single-cell RNA-Seq analysis. We extend these observations to the lung tissue and show that cryopreservation 
of human lung parenchyma as small tissue pieces is also compatible with downstream processing using the 10x 
Genomics single-cell profiling platform. Additionally, a recent preprint demonstrated that cryopreservation of  
tumors as solid tissue or dissociated cell suspensions preserves tumor heterogeneity and complexity and pro-
vides high-quality single-cell transcriptome data (64). However, small biases in population proportions might 
occur in cryopreserved samples, as indicated by a depletion of some epithelial cells after cryopreservation of  
single-cell suspensions of dissociated mouse kidney (60) or human endometrium biopsies (65). Therefore, care-
ful consideration of the experimental design and consistency across samples for a given tissue is recommended.
As previously shown for other lung cryopreservation protocols (27, 28, 31, 49), we demonstrate that 
viable epithelial and mesenchymal cells can be successfully isolated from different compartments of  cryo-
preserved lung material. Our workflow could be further expanded to other cell lineages, such as immune 
cells, since their high viability was also preserved during cryopreservation. Importantly, we show that basal 
epithelial cells isolated from cryopreserved tissue retain their progenitor function and can differentiate into 
ciliated and goblet cells, opening the possibility of  using our platform to model diseases in vitro. Due to its 
simplicity, our workflow is particularly suitable for the establishment of  larger collections of  patient-derived 
material (e.g., lung biopsies) that could enable generation of  patient-derived organoids for personalized 
drug screening, as it is already done for other organs, like the pancreas, kidney, or intestine (32, 66–69).
Finally, as our tissue processing step involves the separation of  distinct lung compartments (airway, 
vessels, parenchyma, tumor), the isolated cells could be used to study crosstalk between multiple cell types 
from the same donor or between cells from healthy and diseased donors. Such strategies would allow the 
development of  more complex and relevant disease models for drug screening and facilitate investigation 
of  interactions occurring in the lung microenvironment in both healthy and disease states.
In summary, with this simple yet powerful workflow, we hope to encourage prospective collections of  
well-characterized human lung tissue samples that could be used for cell type–resolved NGS-based profil-
ing and disease modeling using primary human cells, boosting future basic and translational research.
Methods
Patient samples. Specimens were obtained from the Thoraxklinik Heidelberg (Heidelberg, Germany), the 
Asklepios Biobank (Gauting, Germany), and the University of  Texas Health Science Center (Houston, 
USA). Human tissue samples (tumor or lung parenchyma) were obtained from patients undergoing lung 
surgery due to primary lung SCC or adenocarcinoma who had not received chemotherapy or radiation 
within 4 years before surgery. Normal human lung tissue was obtained from the International Institute for 
the Advancement of  Medicine, from lungs rejected for transplantation for reasons unrelated to obvious 
acute or chronic pulmonary disease.
Emphysema score index determination. Lung and emphysema segmentation were performed by calculating 
the emphysema score index (ESI) from clinically indicated preoperative CT scans taken with mixed techni-
cal parameters. After automated lung segmentation using the yet another CT analyzer (YACTA) software, a 
threshold of –950 Hounsfield units (HU) was used with a noise correction range between –910 and –950 HU to 
calculate the relative amount of emphysema in % of the respective lung portion (70). While usually global ESI 
was measured, the contralateral nonaffected lung side was used if  a lung was severely affected by the tumor.
FFPE and H&E. Representative slices from different areas of  the tissue and tumor samples were fixed 
overnight (O/N) with 10% neutral buffered formalin (MilliporeSigma). Next, fixed tissue samples were 
washed with PBS and kept in 70% ethanol at 4°C. Sample dehydration, paraffin-embedding, and H&E 
staining were performed at Morphisto GmbH (Frankfurt, Germany). Per sample, 2 sections, 4 μm thick, 
were cut on a Leica RM2255 microtome with an integrated cooling station and water basin and transferred 
to adhesive glass slides (Superfrost Plus, Thermo Fisher Scientific). Subsequently, the sections were dried 
O/N in a 40°C oven to remove excess water and enhance adhesion (see Supplemental Table 2 for details). 
H&E-stained slides were evaluated by an experienced lung pathologist at the Thoraxklinik in Heidelberg.
Cryopreservation of  primary SCC tumor samples. Freshly excised lung tumors were transported in CO2-in-
dependent medium supplemented with 1% BSA, penicillin/streptomycin, and amphotericin (CO2-i
+++, see 
Supplemental Table 1 for details); washed with cold HBSS; and minced with a sterile razor blade and eye 
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scissors into 4 × 4 mm pieces. Then 10–15 tissue pieces were transferred to cryotubes (Sarstedt) and covered 
with 1.4 mL ice-cold freezing medium (DMEM supplemented with 10% DMSO and 20% FBS), flipped to 
distribute the medium within the tissue pieces, and kept on ice for 15 minutes. Tubes were placed in Mr. 
Frosty containers (Thermo Fisher Scientific) and transferred to –80°C to ensure a cooling rate (1°C/min). 
For long-term storage, samples were kept in liquid nitrogen.
Cryopreservation of  lung parenchyma and airway- and vessel-enriched fraction. Lung specimens were transport-
ed in CO2-i
+++ (Supplemental Table 1). Tissue pieces were carefully inflated with cold HBSS++++ (Supple-
mental Table 1), and exemplary samples of  the different areas of  the lung piece were collected for histologi-
cal analysis (see above). The pleura was carefully removed from the remaining tissue and airways and vessels 
separated from the parenchyma as much as possible and cryopreserved separately. The parenchymal airway- 
and vessel-free fraction was further minced with a sterile razor blade and eye scissors into 4 × 4 mm pieces. 
Then 10–15 pieces were transferred to cryotubes, covered with 1.4 mL ice-cold freezing medium (Supple-
mental Table 1), kept on ice for 15 minutes, and transferred to –80°C in Mr. Frosty containers to ensure a 
gradual temperature decrease (1°C/min). For long-term storage, samples were kept in liquid nitrogen. For 
the airway- and vessel-enriched fraction, after mincing, 5 to 6 pieces of  tissue were transferred to cryotubes, 
covered with 1.4 mL ice-cold CryoStor freezing medium (Supplemental Table 1), kept 15 minutes in ice, and 
transferred to –80°C in Mr. Frosty containers. The next day, tubes were transferred to a liquid nitrogen tank.
Tissue dissociation, viability check, and FACS. Cryopreserved lung and tumor tissues were thawed for 2 min-
utes in a 37°C water bath, collected in 50 mL Falcon tubes (Neolab Migge), and washed with HBSS++++ (see 
Supplemental Table 5 for details). Fresh and thawed tissue samples were minced into smaller pieces before 
mechanical and enzymatic dissociation. Tissue pieces were dissociated into single-cell suspensions with the 
human tumor dissociation kit following manufacturer instructions (Miltenyi Biotec) and published protocols 
(71, 72). Briefly, 1 g of  minced tissue was added to a MACS C tube containing 4.5 mL of CO2-i
+++ (Supple-
mental Table 1), and the enzyme mix from the human tissue dissociation kit (Miltenyi Biotec), consisting 
of  200 μL enzyme H, 100 μL enzyme R, 50 μL enzyme A, 10 μM ROCK inhibitor (Y-27632), and 100 μL 
DNase I, was added (Supplemental Table 5). Tubes were tightly closed and introduced into the MACS dis-
sociator for mechanic disruption, and the following recommended program for lung tissue was performed: 
program h_tumor_01, followed by a 15-minute incubation at 37°C on a rotator; h_tumor_01, plus 15 minutes 
at 37°C on a rotator; h_tumor_02, and 15 minutes at 37°C on a rotator for a final enzymatic dissociation 
and a last mechanical shearing using the program h_tumor_02. The samples were pipetted up and down to 
help with disaggregating. Finally, the enzymatic reaction was stopped by adding 20% FBS (Gibco, Thermo 
Fisher Scientific), and single cells were collected by sequential filtering through 100 μm, 70 μm, and 40 μm 
cell strainers (BD Falcon). Cells were centrifuged 8 minutes at 4°C and 200g, resuspended in ACK lysis buffer 
(MilliporeSigma), and incubated for 3 minutes at room temperature to lyse erythrocytes. After 2 washes with 
HBSS++++, Fc receptors were blocked with human TruStain FcX (BioLegend, Supplemental Table 6) for 30 
minutes on ice. Immune and epithelial cells were labeled using different CD45 and EPCAM antibodies (Sup-
plemental Table 6) for 30 minutes in the dark at 4°C following manufacturer instructions. Stained samples 
were washed, resuspended in HBSS++++, and added to FACS tubes with 40 μm cell strainer caps. To discrimi-
nate between live and dead cells, we used SyTOX blue as recommended by the manufacturer (Thermo Fisher 
Scientific, Supplemental Table 6). We sorted live, single-cell gated, EPCAM+ cells using a FACSAria II cell 
sorter (BD Biosciences). Sorted epithelial cells were used for single-cell RNA-Seq analysis or plated for subse-
quent culture as indicated below. FlowJo software (Tree Star) was used to analyze the FACS results.
Fibroblast isolation and expansion. Primary human lung fibroblasts were isolated by explant outgrowth 
from fresh or cryopreserved tumor-free tissue derived from distal airway-free lung tissue (parenchymal 
fibroblasts) or small airways (peribronchial fibroblasts) following published protocols (31, 73–75). Briefly, 
6–7 microdissected lung parenchyma or airway pieces were placed per well into 6-well plates, left for 30 
minutes at room temperature without medium to improve explant attachment, and carefully covered with 
1 mL of  DMEM (Thermo Fisher Scientific) supplemented with 2% FBS (Gibco, Thermo Fisher Scientific) 
(DMEM+++, Supplemental Table 3). Explants were left undisturbed for 3–4 days, and afterward the medi-
um was exchanged every 2 days and the outgrowth of  fibroblasts from the explants was followed daily. 
Cells were collected from several explant pieces when reaching 70% confluence to preserve the fibroblast 
heterogeneity. Possible epithelial contamination was prevented by trypsinizing for shorter periods (3 min-
utes, 0.05% trypsin with EDTA, Thermo Fisher Scientific) and keeping the cells in DMEM++ (Supplemen-
tal Table 3). Fibroblasts were used within passages 2–4.
1 3
T E C H N I C A L  A D V A N C E
JCI Insight 2021;6(6):e140443  https://doi.org/10.1172/jci.insight.140443
Basal cell isolation and culture. Primary human basal cells were isolated by explant outgrowth from 
cryopreserved explants derived from small (diameter < 2 mm) or large airways (diameter > 2 mm) fol-
lowing published protocols (42, 76–78). Briefly, tubes containing cryopreserved airway-enriched frac-
tions were rapidly thawed in a 37°C water bath, transferred to a 2.5 cm dish containing soak buffer (see 
Supplemental Table 4 for details of  buffers and media composition), and soaked twice for 5 minutes. The 
soaked airway pieces were washed 3 times with a wash buffer. Airways were microdissected in CO2-in-
dependent medium to remove the remaining parenchymal tissue around them. Microdissected airway 
pieces were placed into individual wells of  a 24-well plate and left in culture with PneumaCult Ex+++ 
undisturbed for 7 days. Afterward, the medium was switched to PneumaCult Ex+++ and exchanged every 
2 days. Cells were split at 80% confluence using Lonza’s Reagent Pack Subculture Reagents following the 
manufacturer’s instructions. Basal cells were pelleted at 180g for 5 minutes and seeded for immunofluo-
rescence or expanded for 1–2 passages before seeding for 3D sphere cultures.
Culture and collection of  basal cell–derived 3D spheres. Basal cell–derived 3D spheres were obtained follow-
ing published protocols (40, 42). Cells in passage 1 were trypsinized and resuspended (3 × 104 cells/mL) in 
BEGM* (Lonza, see Supplemental Table 4 for details of  media composition) containing 5% growth-fac-
tor-reduced Matrigel (Corning). A total of  65 μL of  the cell suspension was plated in each well of  a non-
adherent 96-well plate precoated with 30 μL of  a 25% solution of  Matrigel (Corning) in BEGM* (Lonza). 
ROCK inhibitor (5 μm, Y-27632) was added at seeding only, and cultures were fed or treated on days 3, 
8, and 14 of  culture with 70 μL of  BEGM*. On day 21, plates containing 3D spheres were placed on ice. 
The spheres were washed with ice-cold PBS 1X to remove the medium and Matrigel and then collected 
into Eppendorf  tubes. Cells were incubated for 1 hour at room temperature with 4% PFA (Thermo Fisher 
Scientific), washed with 1X PBS, and embedded in Histogel (Thermo Fisher Scientific) following the man-
ufacturer’s instructions. Histogel-embedded spheres were processed and embedded in paraffin at Morphisto 
GmbH as detailed above for the tissue specimens.
Isolation and culture of  primary SCC and distal epithelial cells. Tumor cells were obtained from SCCs and 
distal epithelial cells isolated from cryopreserved lung parenchyma by mechanical and enzymatic dissocia-
tion of  cryopreserved tissue as indicated above. Single-cell suspensions were resuspended in SAGM (Lonza) 
supplemented with 1% FBS (Gibco, Thermo Fisher Scientific) (see Supplemental Table 5 for details).
Afterward, tumor and distal epithelial cells were obtained by modified previously published protocols 
(79–82) and used within passages 1–3. Specifically, single-cell suspensions were spun down, resuspended 
in SAGM supplemented with 1% FBS, and placed for 2 hours into 24-well plates at 37°C. The unattached 
cells were harvested and seeded in new wells and monitored for epithelial growth. When wells contained 
contaminating fibroblasts in P0, differential trypsinization was performed to eliminate them. Briefly, cells 
were washed and incubated for 5 minutes at room temperature with 0.25% trypsin (Lonza’s Reagent Pack 
Subculture Reagents, Supplemental Table 5). Detached cells (mainly fibroblasts) were discarded. If  epithe-
lial cells did not reach 70%–80% confluence, trypsin neutralizing solution (TNS) was added to the wells, 
incubated for 1 minute, and removed, and fresh medium was added to the well. If  epithelial cells reached 
the desired confluence, fresh 0.25% trypsin was added (Lonza’s Reagent Pack Subculture Reagents, Supple-
mental Table 5), and plates were further incubated at 37°C for 6 minutes. Reaction was stopped with TNS; 
cells were spun down and resuspended in SAGM supplemented with 1% FBS.
Epithelial cells were isolated by FACS as indicated in the tissue dissociation section above using EPCAM 
antibodies and cultured with SAGM supplemented with 1% FBS (Supplemental Tables 5 and 6). Additional-
ly, distal alveolar epithelial cells were successfully isolated by explant outgrowth as previously reported with 
minor modifications (83). Briefly, cryopreserved lung parenchyma pieces were further minced and placed 
into individual wells of  a 24-well plate and left 30 minutes at room temperature for better attachment to the 
bottom. A total of  200 μL of the SAGM (Lonza) supplemented with 1% FBS (see Supplemental Table 5 for 
details) was added to each explant well and the plate left undisturbed for 5 days. Afterward, 500 μL of the 
SAGM (Lonza) supplemented with 1% FBS (Gibco, Thermo Fisher Scientific) was added to each well and 
the medium replaced every other day. Explants were monitored and cells split at 80% confluence using the 
Reagent Pack Subculture Reagents (Lonza) following the manufacturer’s instructions (Supplemental Table 5).
Immunofluorescence. Ten thousand human lung fibroblasts derived from cryopreserved explants or 
5000 epithelial cells obtained from cryopreserved lung material were seeded per well in a 96-well plate 
(in passage 3 or passage 1, respectively). After 24 to 48 hours, cells were washed with PBS 1X, fixed 
for 10 minutes with 4% PFA (MilliporeSigma) at room temperature, and washed and permeabilized for 
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10 minutes with 0.3% Triton X-100 (Gibco, Thermo Fisher Scientific) at room temperature. Unspecific 
staining was blocked by incubating 1 hour at room temperature with blocking buffer (for details of  
buffer composition and antibodies see Supplemental Table 7). Cells were incubated with the indicated 
primary antibodies overnight at 4°C. Cells were washed with PBS 1× and labeled with respective sec-
ondary antibodies for 40 minutes at room temperature in the dark. Finally, cells were washed with PBS 
1X, counterstained with DAPI (1:5000, MilliporeSigma) for 10 minutes at room temperature, washed 
once more with PBS 1X, and kept at 4°C with PBS 1X until imaging.
Slides containing 4 μm thick slices of  3D spheres were deparaffinized and rehydrated as indicated 
in Supplemental Table 2 (steps 30–38). Heat-induced epitope retrieval was performed in a pH 6.0 citrate 
buffer (pH 6.0, Abcam) (Supplemental Table 2, step 39) for 20 minutes at 100°C. Slides were washed, 
permeabilized, and treated as indicated above for immunofluorescence of  cells (Supplemental Table 7). 
Finally, 3D sphere–containing slides were mounted with ProLong Antifade reagent (Thermo Fisher Scien-
tific) (Supplemental Table 7) containing DAPI. Microscope slides were left to dry overnight before imaging.
Imaging of  cells and spheres was conducted at the Zentrum für Molekulare Biologie der Universität 
Heidelberg Imaging Facility (Heidelberg) using the Zeiss LSM780 confocal fluorescence microscope.
RNA isolation and RNA-Seq. A total of  2 × 105 primary human lung fibroblasts obtained from fresh and 
cryopreserved explants from 3 donors in 2–5 technical replicates were harvested at passage 3. Total RNA 
was isolated using the RNeasy Plus Micro Kit (Qiagen) following the manufacturer’s instructions (for details 
of  reagents please see Supplemental Table 8). DNA was removed by passing the lysate through the genomic 
DNA eliminator column provided with the kit and by on-column DNase treatment before elution (Qiagen). 
RNA was eluted using nuclease-free water (Thermo Fisher Scientific) and the concentration measured with 
Qubit RNA Assay Kit in Qubit 3.0 Fluorometer (Thermo Fisher Scientific). RNA integrity was assessed using 
the RNA Pico 6000 Assay Kit of  the Bioanalyzer 2100 system (Agilent Technologies), and only samples 
with RIN higher than 8 were processed further. Stranded mRNA-Seq libraries were prepared at the EMBL 
GeneCore from 200 ng of  total RNA using the Illumina TruSeq RNA Sample Prep v2 Kit implemented 
on the liquid handling robot Beckman FXP2. The libraries were pooled in equimolar amounts, and 1.8 pM 
solution of  each pool was loaded on the Illumina sequencer NextSeq 500 high output and sequenced unidi-
rectionally, generating approximately 450 million reads per run, each 75 bases long.
Alignment and transcript abundance quantification. Single-end reads from the RNA-Seq experiment were 
mapped to the human genome version 37 and the reference gene annotation (release 70, Ensembl) using 
STAR v2.5.0a (84) with following parameters: --outFilterType BySJout --outFilterMultimapNmax 20 
--alignSJoverhangMin 8 --alignSJDBoverhangMin 1 --outFilterMismatchNmax 999 --alignIntronMin 20 
--alignIntronMax 100000 --outFilterMismatchNoverReadLmax 0.04 --outSAMtype BAM SortedByCoor-
dinate --outSAMmultNmax 1 --outMultimapperOrder Random.
The contamination of  PCR duplication artifacts in the RNA-Seq data was controlled using the R pack-
age dupRadar (85). The featureCounts script (86) of  the Subread package v1.5.3 was used to assign and 
count mapped reads to annotated protein-coding and long noncoding RNA genes with default settings.
Exploratory data analysis. For exploratory RNA-Seq data analysis, the data needed to be homoscedastic. 
Therefore, the raw counts were transformed by the regularized-logarithm transformation rlog built in to the 
DESeq2 Bioconductor package (87). The 500 genes with the highest variance in expression across all sam-
ples were subjected to PCA using the R function prcomp and to hierarchical clustering using the pheatmap 
Bioconductor package (88).
DNA extraction and Infinium MethylationEPIC BeadChip assay. Genomic DNA was extracted from 2 × 
105 primary human lung fibroblasts isolated from fresh and cryopreserved tissue from 3 donors in technical 
replicates using QIAamp Micro Kit (Qiagen) following the manufacturer’s protocol, with an additional 
RNase A treatment step (Qiagen).
Infinium MethylationEPIC BeadChip assay genome-wide DNA methylation profiles of  human lung 
fibroblasts were generated using Illumina’s Infinium MethylationEPIC Bead Chip assay (EPIC Array) at 
the Genomics and Proteomics Core Facility at DKFZ (Heidelberg, Germany). The assay allows determi-
nation of  DNA methylation levels at more than 850,000 CpG sites and provides coverage of  CpG islands, 
RefSeq genes, ENCODE open chromatin, ENCODE transcription factor binding sites, and FANTOM5 
enhancers. The assay was performed according to the manufacturer’s instructions and scanned on an Illu-
mina HiScan. To avoid batch effects, both fresh and cryopreserved samples from the same donor were 
assayed on the same array.
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Infinium MethylationEPIC BeadChip data processing. Primary array data as IDAT files were loaded into 
R and preprocessed using the package RnBeads (43). In addition, we applied stringent filtering to exclude 
probes potentially overlapping with common genetic variants (dbSNP v.150) with minor allele higher or 
equal to 1% within 3 bp from the queried CpG position (PCA, correlation analysis on all probes and heat-
maps as in the case of  gene expression, with the 5000 most variable sites). Differential methylation analysis 
was performed using RnBeads. In brief, a linear model with cryopreservation as an independent indicator 
variable was fit, and the corresponding coefficient was tested for significance using limma package (89). 
Adjustment for multiple testing was performed using Benjamini-Hochberg method (90).
Single-cell RNA-Seq library preparation. EPCAM+ FACS-sorted cells from 3 donors with normal lung 
function as determined by spirometry and normal lung morphology confirmed by pathological evaluation 
were spun down, resuspended in HBSS++++ (Supplemental Table 1, Supplemental Table 5, and Supple-
mental Table 11), and counted. Samples were submitted to the EMBL GeneCore for processing on 10x 
Genomics Chromium and sequencing. Briefly, 8700 living EPCAM+ epithelial cells were loaded into the 
10x Genomics Chromium controller using chip A according to the manufacturer’s protocol. Reverse tran-
scription, cDNA amplification, and the subsequent library preparation from 250 ng of  cDNA were per-
formed following 10x Genomics Single Cell 3′ gene expression protocol. The finished libraries were pooled 
and sequenced using Illumina NextSeq 550 instrument with an asymmetric read mode 26 bp read 1 with 
an 8 bp index read and 58 bp read 2.
Single-cell RNA-Seq data processing, alignment, clustering, and cell type classification. The 10x single-cell 
RNA-Seq data were processed using the Cell Ranger (v3.0.0) analysis pipeline (default parameters). 
Reads were aligned against the human reference genome GRCh38. The Seurat (v3.0.1) R package was 
used for downstream data analysis. For each sample, we filtered out cells with unique molecular iden-
tifiers < 500, unique molecular identifiers > 2500 (>3 SD from the mean), and mitochondrial mapping 
percentage > 10%. Normalization for technical confounders and variance stabilization was based on 
regularized negative binomial regression and the sctransform (v0.2.0) R package with default parame-
ters. The mitochondrial mapping percentage was further regressed out in an additional nonregularized 
linear regression step. The integration of  all 3 lung data sets was based on the Seurat v3 integration 
workflow (default parameters). A graph-based clustering approach was used to identify cell clusters. 
Briefly, the first 50 principal components were used to build a K-nearest neighbor graph, and cell clus-
ters were identified using the Louvain algorithm (resolution = 2.0). Visualization of  cell clusters was 
based on a low dimensional projection of  the first 50 principal components using UMAP and the umap 
(v0.2.2) R package (n_neighbors = 30, min_dist = 0.3, metric = cosine). Differentially expressed genes 
between cell clusters and marker genes were identified using Wilcoxon’s rank-sum tests and the FindAll-
Markers Seurat function (logfc.threshold = 0.2, min.pct = 0.2, only.pos = true). Cell clusters were man-
ually annotated and merged into 12 distinct cell types (8 epithelial, 2 endothelial, and 2 stromal) based 
on commonly used markers in the literature as well as genes that were differentially expressed among 
cell clusters. We assessed the quality of  the cryopreservation protocol for single-cell mRNA sequencing 
based on comparison with quality control reports (https://10xqc.com) for fresh (n = 11) and frozen (n 
= 36) human samples (Chemistry Description = Single Cell 3′ v2, scRNA-Seq method = 10x Genomics 
3′ mRNA v2, Transcriptome = GRCh38).
Data availability. The bulk RNA-Seq, Illumina EPIC Array DNA methylation, and single-cell RNA-
Seq data generated in this study have been deposited at the European Genome-phenome Archive, which is 
hosted by the European Bioinformatics Institute and the Centre for Genomic Regulation, under accession 
number EGAS00001004477.
Statistics. A paired nonparametric test (Wilcoxon’s matched pairs signed-rank test, GraphPad Prism 
software, version 8.0.1) was employed to compare the viability between fresh and cryopreserved lung 
tissue from the same donor. To compare the viability between cryopreserved material from control versus 
COPD samples, unpaired nonparametric t test was employed (Mann-Whitney test). The P value of  0.05 
was considered significant.
Study approval. The protocol for tissue collection was approved by the ethics committees of the University of  
Heidelberg (S-270/2001), Ludwig-Maximilians-Universität München (projects 333-10 and 17-166), and institu-
tional review board of University of Texas Health Science Center at Houston (HSC-MS-08-0354) and followed 
the guidelines of the Declaration of Helsinki. All patients gave written informed consent before inclusion in the 
study and remained anonymous in the context of this study.
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